Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease.
Pham
P-T T
PT
Division of Nephrology, Kidney, and Pancreas Transplantation, Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA.
Wilkinson
A H
AH
Gritsch
H A
HA
Pham
P C T
PC
Miller
J M
JM
Lassman
C R
CR
Danovitch
G M
GM
D000328:Adult; D001741:Black or African American; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology*; D002140:California; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy*; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D018951:Antigens, CD20; D007166:Immunosuppressive Agents; D000069283:Rituximab